


Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>

Contents lists available at [SciVerse ScienceDirect](http://www.sciencedirect.com)

Journal of Controlled Release

journal homepage: www.elsevier.com/locate/jconrel

Cover story

Cardioprotective properties of Tat-BH4 and Pip2b-BH4 *in vivo*

Each year 17 million people die from cardiovascular diseases, mainly acute myocardial infarction (AMI) and stroke. AMI is a disabling disease leading to heart failure and death. More specifically, coronary heart disease is the most common cause of death in the U.S., in Europe and in industrialized countries causing the death of approximately one in five men and one in six women. Infarct size is a major determinant of myocardial functional recovery and mortality after acute myocardial infarction (AMI) [1]. Limitation of infarct size is required to prevent post-ischemic heart failure and improve survival. Prompt revascularization of AMI by reperfusion (using thrombolysis or primary coronary angioplasty) leads to improved functional myocardial recovery and increased patient survival dramatically [2, 3].

Unfortunately, the reestablishment of blood circulation providing oxygen to hypoxic tissues activates apoptotic cascades that culminate in death of cardiac cells that were viable before reperfusion [4, 5]. Lethal reperfusion injuries contribute to about 50% to the final infarct size. Since no pharmacological agent has proven efficient so far, interrupting apoptotic cascades with peptides has been considered as a potential strategy to prevent reperfusion injuries. The BH4 (for Bcl2-homology) domain is shared by several pro-apoptotic proteins and its anti-apoptotic properties have been demonstrated in several *in vitro* models. However, relatively large hydrophilic entities as peptides do not cross biological barriers. Their association with delivery vectors such as cell penetrating peptides (CPPs) has therefore been proposed to improve bioavailability.

The anti-apoptotic activity of constructs in which the BH4 peptide was appended to the Tat CPP was documented in cardiac cells and in the Langendorff reperfusion heart model but no *in vivo* evaluation has yet been published. Since new CPPs with seemingly improved ability to deliver biomolecules in muscle cells have been described recently, several such CPP-BH4 constructs were initially evaluated in primary cardiomyocytes. None was found more efficient than Tat-BH4 in terms of anti-apoptotic activity thus confirming that the CPP vector needs to be optimized for each transported cargo. The two most efficient constructs, Tat-BH4 and Pip2b-BH4, were then evaluated *in vivo* in a murine model of ischemia/reperfusion (I/R) [6]. In brief, ischemia was induced by a ligation of the left coronary artery and reperfusion of the myocardium was obtained by losing the knot. Anti-apoptotic peptidic constructs or control ones were injected in the caudal vein. Remarkably, a single low dose (1 mg/kg) of either Tat-BH4 or Pip2b-BH4 reduces infarct size by about 50% when injected at the time of reperfusion. None of the controls, e.g., the CPP alone or scrambled versions of the CPP-BH4 constructs, had a significant anti-apoptotic activity. Maximal cardioprotection was reached when CPP-BH4 constructs were injected immediately before reperfusion that is just before the reperfusion-induced burst of apoptosis [7]. Moreover, injection 2 h after the beginning of reperfusion has no

more cardioprotective effect. Parallel experiments did show that cardioprotection was accompanied by a reduction of DNA fragmentation, an index of anti-apoptotic activity.

Additional data concerning long-term benefits and toxicity as well as further investigations in other animal models (e.g., pig) will be required to forward the development of therapeutic tools to prevent reperfusion injuries after AMI. Likewise studies currently in progress in the group aim at a better understanding of the mechanism of cardioprotection and of the trafficking of these constructs *in vitro* and *in vivo*. Screening for other cardioprotective peptides or for tissue-specific delivery vectors is continued by the same group. The most unique thing about the cardioprotection by the optimized CPP-peptide constructs is that reduction in infarct size by 50% was achieved by only a low single dose injection at the time of reperfusion. While this may only be the first step demonstrating the possibility of a new treatment, its impact upon successful development into clinical practice will be certainly enormous. Furthermore, similar tools could be used to limit ischemic injuries in other organs and situations.

References

- [1] R.J. Burns, R.J. Gibbons, Q. Yi, R.S. Roberts, T.D. Miller, G.L. Schaer, J.L. Anderson, S. Yusuf, The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis, *J. Am. Coll. Cardiol.* 39 (1) (2002) 30–36.
- [2] E. Braunwald, Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? *Circulation* 79 (2) (1989) 441–444.
- [3] P.G. McGovern, J.S. Pankow, E. Shahar, K.M. Doliszny, A.R. Folsom, H. Blackburn, R.V. Luepker, Recent trends in acute coronary heart disease—mortality, morbidity, medical care, and risk factors, The Minnesota Heart Survey Investigators. *N. Engl. J. Med.* 334 (14) (1996) 884–890.
- [4] E. Braunwald, R.A. Kloner, Myocardial reperfusion: a double-edged sword? *J. Clin. Invest.* 76 (5) (1985) 1713–1719.
- [5] D.J. Hausenloy, D.M. Yellon, Preconditioning and postconditioning: new strategies for cardioprotection, *Diabetes Obes. Metab.* 10 (6) (2008) 451–459.
- [6] P. Boisguerin, C. Redt-Clouet, A. Franck-Miclo, S. Licheheb, J. Nargeot, S. Barrere-Lemaire, B. Lebleu, Systemic delivery of BH4 anti-apoptotic peptide using CPPs prevents cardiac ischemia-reperfusion injuries *in vivo*. *J. Control. Release* 156 (2011) 150–157.
- [7] F. Roubille, A. Franck-Miclo, A. Covinhes, C. Lafont, F. Cransac, S. Combes, A. Vincent, P. Fontanaud, C. Sportouch-Dukhan, C. Redt-Clouet, J. Nargeot, C. Piot, S. Barrere-Lemaire, Delayed postconditioning in the mouse heart *in vivo*, *Circulation* 124 (12) (2011) 1330–1336.

Kinam Park
Purdue University,
Departments of Biomedical Engineering and Pharmaceutics,
West Lafayette, Indiana, USA
E-mail address: kpark@purdue.edu